Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
13.17
-0.66 (-4.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 12, 2021
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life...
Via
Benzinga
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 12, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
July 11, 2021
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...
Via
Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...
Via
Talk Markets
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...
Via
Benzinga
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)
June 28, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
June 05, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 27, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Kalvista Pharmaceuticals Stock Shows Rising Relative Strength
May 19, 2021
A Relative Strength Rating upgrade for Kalvista Pharmaceuticals shows improving technical performance.
Via
Investor's Business Daily
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
May 10, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
May 03, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
31 Stocks Moving In Tuesday's Mid-Day Session
April 20, 2021
Gainers MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) gained 20.8% to $5.32 after dropping more than 10% on Monday. Takung Art Co., Ltd. (NASDAQ: TKAT) shares surged 18.2% to $21.08...
Via
Benzinga
Why Crispr, KalVista And Syndax Are Moving Today
April 20, 2021
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma...
Via
Benzinga
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
April 20, 2021
Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
April 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...
Via
Benzinga
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
April 20, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.